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Abstract
Men diagnosed with early stage prostate cancer face multiple
treatment options, each with distinctive side effects that have
significant implications for post-treatment quality of life. Healing
Choices for Men with Prostate Cancer is a multimedia educational
and decision aid program. This nation-wide randomized controlled
trial evaluated the impact of Healing Choices on reducing decisional conflict and distress. Eligible prostate cancer patients who
called the National Cancer Institute's Cancer Information Service
(CIS) were invited to participate. After a baseline interview, participants were randomized to usual personalized consultation with a
CIS specialist (comparison condition) or CIS personalized consultation plus the Healing Choices program (intervention condition).
The Decision Conflict Scale and Impact of Event Scale assessed
decisional conflict about prostate cancer treatment and cancer-related distress, respectively. Analyses evaluated group differences
at 2 months postenrollment. Hypothesized moderation of intervention effects by demographic and clinical characteristics were
evaluated. The final sample consisted of N = 349 participants
(intervention: n = 181; comparison n = 168). Men were on
average 64 years old, primarily White, and well educated. The
difference in total decisional conflict was not significant (DCS total
score; F[1,311] = .99, p = .32). The difference in cancer-related
distress at 2 months between the intervention and the comparison groups was not significant (F[1,337] = .01, p = .93).
Evaluation of specific decision processes indicated a significant
effect on levels of perceived decisional support (intervention,
M = 34.8, SD = 15.7; comparison, M = 38.3, SD = 16.1;
F[1,337] = 3.74, p = .05). The intervention effect was greatest
for nonwhite minority participants (b = −9.65, SE = 4.67) and
those with lower educational attainment (b = 3.87, SE = 2.21).
This interactive, comprehensive education and decision aid
program may be most effective for a subset of prostate cancer
patients in need of educational and decisional support.
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INTRODUCTION

Treatment options for men diagnosed with localized
prostate cancer, defined as a tumor that is confined
to the prostate without nodal involvement or distant
metastases (T1,T2,N0,M0), include surgery, radiation
therapy (i.e. external beam radiation, brachytherapy),
and active surveillance [1,2]. The 5-year survival rate

Implications

Practice: Efficient and effective screening methodologies need to be developed and integrated
into clinical practice to help identify patients in
greatest need for additional support.
Policy: One-size-fits-all approaches to patient
information and support are not successful and
therefore it is necessary to direct policies and
funds toward the development, maintenance,
and support of various information channels to
aid an increasingly diverse patient population.
Research: Further research is needed to identify
prostate cancer patients who would most benefit
from supportive interventions and how to best
integrate such programs within existing clinical
resources.

with active treatment approaches 100%, although
often at the cost of significant, potentially long-lasting urinary, sexual, and bowel dysfunction [3–6].
Because of the various treatment choices available to
patients and the risk to future quality of life, treatment
decisions for prostate cancer are considered preference sensitive [7]. Preference sensitive decisions are
informed by clinical parameters as well as patients’
values and goals for future outcomes and are ideally
achieved in an information exchange and values clarification process between providers and patients. In
practice, such a decision situation is rarely achieved
and patients routinely have to resolve contradictory
medical opinions from physicians representing different medical subspecialties [8]. The decision is further
complicated by disease and treatment information
that is often presented in medical and probabilistic
terms [8–10], often leading to a challenging decision-making process, elevated levels of distress, and,
for some patients, long-term decision regret [7].
To facilitate patient education and decision-making, researchers have begun to develop
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evidence-based interactive, multimedia educational
programs as an adjunct to cancer care [11–14]. These
programs have been used to help prepare patients
for medical procedures, provide health information,
teach coping strategies, and facilitate patient–physician communication [15]. A growing literature has
demonstrated that these educational approaches
can be very effective, leading to improved knowledge about treatment options, reduced anxiety and
cancer-related worries, and increased confidence in
patients’ interaction with their healthcare providers [15–17]. However, patients access information
from multiple sources (e.g. advice/guidance from
family and friends, media) [8,18] and bring unique
cognitive and affective experiences (e.g. risk and
treatment-related perceptions, expectations, fears)
to the decision-making process. These factors will
inevitably influence patients’ assessment of information and increase their need for decision support.
Even well-informed patients may require support to
integrate personal values and preferences into their
decision-making, especially when faced with a lack
of consensus among medical providers about the
best treatment approach.
Education and decision aids are often implemented at the point of care. Healthcare providers
introduce the tool, help with completion, and ideally discuss treatment preferences with their patients.
However, this places providers as a gateway to implementation of such tools and limits the reach of decision support intervention. To expand our reach and
to target patients across the USA, we partnered with
the National Cancer Institute’s Cancer Information
Service (CIS) with the goal to augment their existing telephone-based information service. Our newly
developed education and decision aid, the Healing
Choices program, was designed to complement this
telephone-based information service and included
video-based information from physicians and survivors, an interactive value clarification module, as
well as strategies to deal with distress and to enhance
patient–physician communication [11]. Our partnership with the CIS afforded us the opportunity to
evaluate the utility of the tool in a pragmatic fashion
in the context of an established life-telephone service.
Prostate cancer patients who call the CIS’s toll-free
number (1-800-4-Cancer) can receive detailed information from a trained cancer information specialist
about their cancer, its treatment options, potential
treatment side effects, and ongoing clinical trials.
This standard consultation was the comparison condition in the present study. The study intervention
condition received the standard consultation and
services plus access to the Healing Choices program.
Theoretical framework

Self-regulation theory [19] and social cognitive theory [20] guided the development of the intervention
and the selection of study measures. Self-regulation
TBM

theory postulates that decision-making for health
behaviors is influenced by cognitive and affective
processes. Cognitive processes consist of representations, such as beliefs about illness-related causes,
consequences, duration, controllability, and overall
understanding (i.e. illness cohesion). Affective processes are emotional reactions to the illness, such as
worry about the disease and its treatment. Concepts
postulated by the self-regulation theory were translated into the content and the design of the Healing
Choices program in the following ways: providing
cancer-relevant information using a virtual library
that provides information about treatment options
and side effects; addressing individual beliefs and
expectations about cancer treatment and disease
outcomes through patient testimonials and physicians answering questions; providing emotional
support through normalizing statements and a distress-lowering exercise; and modeling skills for decision-making (role models) to enhance self-efficacy in
patient–physician communication and for generating and maintaining goal-oriented health-protective
behaviors [21–24].
The impact of the Healing Choices program in
facilitating treatment decision-making and reducing
decisional conflict and cancer-related distress was
evaluated in a nation-wide randomized controlled
pragmatic trial. Eligible callers were randomized
to receive standard consultation with a CIS information specialist via one phone call contact versus
standard consultation plus access to the Healing
Choices program. We hypothesized that patients in
the intervention group would report lower levels
of decisional conflict compared with patients in
the comparison group (i.e. those receiving consultation with a cancer information specialist and NCI
materials only). We also hypothesized that patients
in the intervention group would report lower levels
of cancer-related distress compared with patients
in the comparison condition. The study examined
whether the impact of the intervention on decisional
conflict and cancer-related distress would be moderated by patients’ demographic and clinical characteristics (e.g. age, race, education, and comorbidity).
Based on the literature [25–28], we hypothesized
that older, nonWhite patients with lower education
and more comorbid diseases would benefit more
from the intervention than younger, White patients
with higher education and less illness burden.
METHODS

All research protocols and materials were approved
by the Institutional Review Board (IRB) of the
University of Colorado Denver, Anschutz Medical
Campus. IRB approval was also obtained from the
collaborating research institutions (i.e. University
of California, Los Angeles and Fox Chase Cancer
Center) and from parent institutions of the three
CIS contact centers (i.e. University of Miami, Fred
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Hutchinson Cancer Research Center, and Memorial
Sloan-Kettering Cancer Center). The trial was registered on www.clinicaltrials.gov (NCT00830635).
The study was conducted between 2009 and the
end of 2014.
Inclusion/exclusion criteria and recruitment procedures

Recruitment procedures and challenges are
described elsewhere [29]. In short, men who called
the CIS about prostate cancer or its treatment
were recruited at the end of their standard service
telephone call by cancer information specialists.
Eligibility was ascertained and verbal consent was
obtained over the phone. Patients were eligible if
they were diagnosed with localized prostate cancer
(T1,T2,N0,M0), had not made a treatment decision,
had access to a computer, and were English speaking. Exclusion criteria were completion of prostate
cancer treatment, presence of other primary cancer,
or cancer recurrence. Enrollment and a brief baseline assessment were also conducted over the phone
at this time.
The majority of patients were recruited through
the CIS. However, a slower than expected recruitment pace exacerbated by CIS internal reorganization made it necessary to establish additional
recruitment approaches. This resulted in the establishment of a new call center from the CIS research
consortium and a new collaboration with the
American Cancer Society’s (ACS) call center [29].
Cancer education specialists from the ACS were
trained by the study personnel following a trainthe-trainer model. Other accrual sources included
recruitment flyers/print materials, CIS Research
Consortium Websites, community outreach and
word-of-mouth efforts, and NCIS-related information on the radio; none of which accounted for a
substantial number of participants alone.
Randomization procedure

Immediately following the completion of the baseline interview, eligible callers who agreed to participate in the study were randomized to either usual
service with a standard consultation (comparison
condition; Group 1) or standard consultation plus
the Healing Choices program (intervention condition;
Group 2; see Figure 1). Group 1 received cancer
information by telephone and standard print NCI
materials. Group 2 received information by telephone, the NCI print materials, plus access to the
multimedia Healing Choices software. All print materials, including an introductory letter, were shipped
via express mail and received by study participants
within 48 hours of the patient’s call to the CIS. In
addition, participants assigned to Group 2 subsequently received a CD-ROM version of the multimedia program, as well as information on how to
access the Healing Choices program on the Internet.
All Group 2 participants received a second letter

14 days after study enrollment to encourage use of
the program. Telephone follow-up interviews were
conducted by blinded research staff at 2 months to
assess decisional conflict and cancer-related distress
and at 6 months postenrollment to assess decisional
regret and distress. Because the primary focus of the
project was to facilitate decision-making and reduce
cancer-related distress with regard to treatment decision-making, only data from the 2-month evaluation
were analyzed based on its temporal proximity to
the decision-making process [12]. It was not possible
to conceal allocation to study group.
Usual care comparison condition

All men who were randomized into the comparison usual service condition spoke with a cancer
information specialist from the CIS to have their
specific questions answered and to receive personalized information about prostate cancer, treatment
options, potential side effects, and existing clinical
trials. As part of this standardized service, they also
received the CIS standard NCI print materials,
which included What You Need to Know about Prostate
Cancer (NIH publication No. 12–1576) and Treatment
Choices for Men with Prostate Cancer (NIH publication
No. 11–4659).
Intervention condition

Men who were randomized to the intervention condition received the usual service provided by the
CIS and had the opportunity to participate in the
Healing Choices program.
Healing Choices for men with prostate cancer
The development of the software was described by
Marcus et al. [30]. In short, the selection of content
for the software was guided by our theoretical framework, based on a comprehensive literature review,
and supplemented with disease- and treatment-relevant information. All information was vetted by the
CIS to meet NCI standards. Content was organized
in four different areas that addressed the major identified needs of prostate cancer patients as guided by
the conceptual framework. They were The Library,
Patient Stories, Doctor’s Office, and the Notebook [11].
The Library, contained factual information (written at
a 7th grade reading level) about prostate cancer and
its treatment options; Patient Stories contained videos
of disease and treatment experiences recounted by a
group of ethnically diverse patients who had undergone different treatments; Doctor’s Office provided
the physician’s view of treatment and recovery;
and finally, the Notebook provided the user with the
opportunity to determine his values and preferences
regarding treatment and future quality of life as well
as provides distress management skills training and
exercises. The software program underwent extensive User Testing and Usability Testing before it was
released for study purposes.
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Fig. 1 | Overview of research design

STUDY MEASURES
Baseline demographic characteristics

Baseline measures included demographic (e.g.
age, education, race/ethnicity, income, medical
insurance) and clinical characteristics (e.g. cancer
stage, comorbidity). Comorbidity was assessed by
the Charlson Co-Morbidity scale [31]. This widely
used measure is a weighted index that takes into
account the number and seriousness of comorbid
diseases (e.g. liver disease, diabetes) with higher
scores indicating higher comorbidity and illness
burden.
Decisional conflict

At 2 months after baseline, participants completed
the Decisional Conflict Scale (DCS) [32,33], which
consists of five subscales; Decisional Support
TBM

(3 items); Feeling Informed (3 items); Values
Clarity (3 items); Decisional Uncertainty (3 items);
and Effective Decision (3 items); one of the four
questions from the published version of the DCS
Effective Decision subscale (“I expect to stick to my
decision”) was not included. All subscales employ a
five point Likert response scale from “0 – Strongly
Agree” to “4 – Strongly Disagree.” Exploratory factor analyses on the study data confirmed the structure of the five subscales. The full scale and the
five subscales have strong psychometric properties
with a mean Cronbach’s α of .84 (i.e. Cronbach’s
α: Total scale = .93; Feeling Informed = .70; Values
Clarity = .81; Decisional Support = .78; Decisional
Uncertainty = .79; Effective Decision = .83). A mean
score was used to indicate the level of decisional
conflict with higher scores indicating higher levels
of conflict.
page 879 of 886
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Cancer-related distress

Cancer-related distress was assessed at the baseline and 2-month follow-up time points using the
Intrusion subscale of the Impact of Event Scale
(IES) [34]. The subscale referred to the experience
of being diagnosed with prostate cancer. It is composed of seven items that are answered on a four
point Likert scale (0–5) with labels of “Not at all”
(0), “Rarely” (1), “Sometimes” (3), and “Often” (5).
It has been widely used and has well-established
psychometric properties (Cronbach’s α in this
study = .82). A higher score indicates higher levels of intrusive thoughts and feelings about prostate
cancer, signifying higher distress. Subscale scores of
20 and above on the IES have been defined as clinically significant distress reactions [35–37].
Statistical analysis

Data were analyzed with the SPSS statistical software
package, version 19.0. Descriptive statistics, t-test,
chi-square test, and analyses of variance (ANOVA)
were used to examine attrition from baseline (t1) to
2-month assessment (t2). Analyses examining the differences between the intervention and the comparison groups in decisional conflict and cancer-related
distress included those participants that completed
the baseline and 2-month assessments. Intervention
effects on decisional conflict and cancer-related distress were evaluated using analysis of covariance
(ANCOVAs) to test for group differences, controlling
for age. The percentage of patients reporting clinically significant levels of cancer-related distress was
also compared between groups as a test of the intervention using chi-square test, based on the validated
IES cut-off score (scores ≥ 20) [35]. Following standard procedures [38], potential moderation effects of
patients’ demographic and clinical characteristics
on postintervention outcomes that demonstrated
significant main effects were explored. Separate
regression models were specified to test the effects
of four moderator variables (age, ethnicity, education, and comorbidity) on levels of decision support
across the two intervention groups (Group 1, comparison condition vs. Group 2, intervention condition). Each model included intervention group
assignment as the independent variable, a moderator variable (dummy coded for categorical variables), and an interaction between the independent
and moderator variables. Following statistical conventions, the coefficient of the interaction term was
evaluated for significance, above and beyond main
2
effects. The R change determined the amount of
variance in decision support that was explained with
the addition of the interaction term.
RESULTS

Presentation of results is divided into four sections
which describe: (1) enrollment and attrition; (2) sample demographic and clinical characteristics; (3) the

impact of the intervention on study outcomes; and
(4) the moderators of the impact of the intervention
on study outcomes.
Enrollment and attrition analyses

The CIS standard service program provided the
majority of study participants (60%; n = 262). Only
one of the CIS outreach efforts, the collaboration
with the ACS (n = 58), provided a noticeable increase
in accrual. All other referral sources produced only
small or no gains in accrual each and were combined for analyses (e.g. Recruitment Flyers/ Print
Materials, CIS Research Consortium Websites,
community organization, or group). Final enrollment was N = 440 across all sources. For analyses,
recruitment source was collapsed into three categories: CIS, ACS, and other. A comparison of the baseline characteristics of participants enrolled showed
no significant differences by recruitment source in
any demographic or medical variables. Recruitment
source did not vary by group assignment.
Of the 440 eligible patients who completed the
baseline assessment, 349 (80%) patients completed
the 2-month assessment. The most common reasons
for attrition (N = 91) were no computer access (30%
of nonusers), no need (17%), technical problems
with the computer (15%), no time or too busy (13%),
and did not know how to use the multimedia program (9%). The overall rate of attrition did not vary
2
by group condition (x = 1.81, p = .20) and reasons
for attrition were similar across groups with the
exception that the intervention group reported computer-related difficulties, which was not applicable
to the standard care comparison group. To examine any potential bias introduced through selective
attrition, we compared patients who completed both
assessments with patients who only completed the
baseline assessment on demographic (e.g. age, race/
ethnicity, employment, education levels, comorbid
disease/conditions) and psychological variables
(e.g. baseline cancer-related distress). Patients who
dropped out were more likely to be younger, White,
highly educated, more emotionally distressed, with
comorbid disease/conditions than those who completed the 2-month assessment.
Demographic characteristics

The majority of the sample was White (76%) and
most had completed college or graduate school
(54%). The average age of participants was 64.73
(SD = 8.39) years old. At baseline, 23% of patients
reported clinically significant levels of prostate cancer-related distress based on the validated IES cutoff score (scores ≥ 20) (see Table 1). There were no
significant differences between the two study groups
in baseline demographic or clinical variables, or
cancer-related distress, with the exception that the
intervention group was slightly younger than the
standard care comparison group (mean difference
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of 1.9 years, t[347] = 2.06, p = .04; see Table 1).
Therefore, age was included as a covariate in comparative and predictive analyses. Subsequent comparative analyses included data only from patients
who completed both the baseline and postintervention assessments (N = 349).
Intervention effects

See Table 2 for analyses of intervention effects. We
compared decisional process variables (i.e. DCS
total score and subscales) between the intervention
and standard care comparison groups at the 2-month
follow-up visit (i.e. postintervention), controlling
for age. The difference in total decisional conflict
was not significant (DCS total score; F[1,311] = .99,
p = .32). Evaluation of decisional process subscales
indicated that patients with access to the Healing
Choices program reported higher levels of decisional
support compared to patients who received standard consultation (intervention, M = 34.8, SD = 15.7;

comparison, M = 38.3, SD = 16.1; F[1,337] = 3.74,
p = .05; covariate adjusted means: intervention, M = 34.9, SE = 1.2; comparison, M = 38.2,
SE = 1.2). The intervention and comparison groups
reported comparable levels of all other decisional
processes including uncertainty (F[1,335] = .03,
p = .86), feeling informed (F[1,333] = .09, p = .76),
clarity of personal values related to the decision
(F[1,330] = 1.92, p = .17), and effective decision-making (F[1,334] = .73, p = .40).
The difference in cancer-related distress at
2 months between the intervention and the comparison groups was not significant (F[1,337] = .01,
p = .93). In both groups, a smaller percentage of
patients reported clinically significant levels of distress
at the 2-month follow-up compared with baseline (8%
reduction in both groups). Based on a validated case
rule indicating clinical levels of cancer-related distress, 30% of the comparison group reported clinically
significant distress at baseline and 19% at follow-up.

Table 1 | Baseline demographic and clinical characteristics

Study groups

Baseline covariates
Recruitment Source
National Cancer Institute’s Cancer
Information Service (CIS)
American Cancer Society (ACS) call
center
Othera
Age
Educational level
High school graduate or less
Some college
College graduate or more
Income (USD)
<$30,000
$30,000–$59,000
$60,000–$79,000
≥ $80,000
Ethnicity
Other
African-American
White
BMI
Comorbidity
Medical insurance
Baseline cancer-related distress
Intrusion subscale
Clinically significant levels of distress
(scores≥20)b

Full sample at baseline
(N = 349)

Intervention
(n = 181)

Comparison
(n = 168)

M ± SD or %

M ± SD or %

M ± SD or %

t or x2

p

60%

61%

58%

2.87

.24

14%

11%

17%

27%
64.73 ± 8.39

28%
63.85 ± 8.59

26%
65.69 ± 8.08

2.06

.04

18.9%
26.6%
54.2%

20.0%
25.6%
54.4%

17.9%
28.0%
54.2%

.40

.82

2.15

.54

21.2%
23.5%
17.8%
30.7%

25.1%
23.4%
20.5%
31.0%

20.1%
27.3%
17.5%
35.1%

2.6%
16.9%
76.2%
27.5 ± 4.4
82.8%
91.6%

2.3%
18.1%
79.5%
27.6 ± 4.0
80.1%
90.2%

3.1%
17.2%
79.8%
27.4 ± 4.7
85.7%
93.1%

.21

.90

−.56
1.92
.73

.58
.17
.39

13.33 ± 8.24
23.2%b

14.2 ± 8.5
26.1%b

12.4 ± 7.8
21.0%b

−1.94
1.24b

.053
.27b

a
Other accrual sources included recruitment flyers/ print materials, CIS Research Consortium Websites, community outreach and word-of-mouth efforts, or NCIS-related
information on the radio.
b
Based on validated case rule of IES scores ≥20 indicating clinically significant or elevated levels of distress [35].

TBM
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Similarly, within the intervention group, the percent
reporting clinically significant distress decreased from
33% at baseline to 20% at follow-up.
Exploring moderating effects

Regression analyses were conducted to examine
whether the impact of the intervention on decisional support was moderated by patients’ age,
race, educational level, and comorbidity (Table 3).
Consistent with hypothesis, race (tested as a twogroup variable; White vs. African American)
emerged as the only significant moderator (β =
−.18; b = −9.65, SE = 4.67, p = .04; F[3,312] = 2.60,
p = .05). African-American participants, compared
with White participants, reported greater decisional
support after having access to the Healing Choices
program than individuals who received standard
consultation alone (Figure 2). Although at the trend
level, findings also suggested that the Healing Choices

program may have varying effects for participants
based on their education level. Patients with lower
levels of education appeared to benefit more from
the intervention with respect to perceived decisional support, compared with patients with higher
levels of education (β = 0.21; b = 3.87, SE = 2.21;
F[3,335] = 2.67, p = .05). No other significant moderation effects emerged indicating that perceptions
of decisional support did not vary by age (β = −.45,
b = −.22, SE = .21; F[3,336] = 1.78, p = .15) or
comorbidity (β = −.08, b = −2.62, SE = 4.72;
F[3,336] = 1.72, p = .16).
DISCUSSION

Based on our pilot data and studies in the published
literature, we collaborated with the National Cancer
Institute’s Cancer Information Service (CIS) to
develop a patient education and decision aid and
to evaluate its effectiveness compared to standard

Table 2 | Group differences by study outcomes

Two-month outcomes
Decision conflict
Total score
Subscale scores:
Uncertainty
Informed
Value Clarity
Support
Effective Decision
Cancer-related distress
Intrusion subscale
Clinically significant levels of distress
(scores ≥ 20)a

Full sample
(N = 349)

Intervention group
(n = 181)

Comparison group
(n = 168)

M ± SD

M ± SD

M ± SD

F

p

36.72 ± 12.31

36.0 ± 12.03

37.50 ± 12.60

.99

.32

45.70 ± 19.26
35.54 ± 15.79
35.18 ± 15.55
36.49 ± 15.98
33.45 ± 13.25

45.46 ± 18.49
35.77 ± 15.35
33.98 ± 14.75
34.82 ± 15.76
32.84 ± 13.20

45.97 ± 20.13
35.27 ± 16.30
36.52 ± 16.34
38.26 ± 16.08
34.13 ± 13.32

.03
.09
1.92
3.74
.73

.86
.76
.17
.05
.40

11.64 ± 9.02
%
19.2%

11.86 ± 9.44
%
19.7%

11.39 ± 8.54
%
18.5%

.01
x2
.07

.93
p
.79

Higher DCS scores indicate higher levels of decisional conflict and higher IES scores indicate higher levels of cancer-related distress.
a
Based on validated case rule of IES scores ≥20 indicating clinically significant or elevated levels of distress.

Table 3 | Multiple regression analyses predicting the moderation effect

Decisional support at 2 months

Baseline predictor
variable
Moderator
Intervention
Intervention ×
Moderator
R2 change
R2 Total

Model 1: Moderation
effect of age

Model 2: Moderation
effect of racea

Model 3: Moderation effect
of education

Model 4: Moderation effect
of comorbidity

β (b, SE b)

β (b, SE b)

β (b, SE b)

β (b, SE b)

0.09 (0.17, 0.16)
0.35 (11.06, 13.64)
−0.45 (−.22, 0.21)

.14 (5.89, 3.36)‡
−.05 (−1.57, 1.97)
−.18 (−9.65, 4.67)*

−0.15 (−3.13, 1.61)*
−0.27 (−8.68, 3.46)*
0.21 (3.87, 2.2146)‡

0.09 (3.71, 3.58)
−0.04 (−1.15, 4.30)
−.08 (−2.61, 4.694)

.003
0.016

0.013*
0.024*

.009
0.023‡

.001
0.015

The results displayed are the second steps of hierarchical regression analyses. R2 change refers to the variance in Decision Support explained by the Intervention x Moderator
interaction term.
‡
p < .10, *p < .05, **p < .01, ***p < .001.
a
Race was tested as a two-group variable comparing Whites (coded 1) with African-Americans (reference group; coded 0).
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Fig. 2 | Intervention effect on decision support moderated by race.

information service consultation. The resulting
Healing Choices for Men with Prostate Cancer was randomly offered to half of the callers who agreed to
be part of the present study. Results from this pragmatic trial were unexpected: there were no significant intervention effects on total decisional conflict
or lowering cancer-related distress. Further evaluation of decisional processes indicated that patients
with access to the Healing Choices program reported
higher levels of decision support at follow-up compared with patients who received standard consultation alone, irrespective of their age. This intervention
effect was greatest for African-American participants
and those with lower educational attainment.
There are several possible explanations as to why
the Healing Choices intervention did not lead to significant differences in overall decisional conflict or
cancer-related distress compared with the standard
comparison condition. Chief among those explanations is the excellent service the CIS provides to its
callers, which was our main reason to partner with
them. The CIS’ powerful standard of care consists
of time-unlimited personalized consultations to any
disease and treatment-related question, in addition
to receiving printed NCI information booklets.
In this context, it is possible that the vast majority
of patients had their questions answered and the
Healing Choices program did not improve their overall information needs.
The results of the moderator analyses deserve
further mentioning however, as they have important implications for future program development
and evaluation. African-American callers reported
that Healing Choices provided increased decisional
support compared with their White counterparts.
It is unclear whether the higher incidence rate
and perceived severity of prostate cancer among
African-Americans might be responsible for this
effect. However, it is clear that despite extensive
TBM

information tailoring, some African-American men
were in need of more decisional support than the
CIS standard services provided.
Another potential explanation for the null findings is that baseline levels and specific sources of
decisional conflict were not assessed due to concerns in the CIS about participant burden with
a telephone-based questionnaire. It may be that
some participants had low decisional conflict from
the start or that unmet informational needs was
their only source of decisional conflict, which was
addressed by the standard information consultation
(received in both the intervention and comparison
conditions). Although participants in the Healing
Choices program had access to interactive videos,
preference clarification exercises and detailed, visually appealing disease and treatment information,
it is unknown whether participants had unmet needs
specific to these resources, aside from information
seeking. Alternatively, we also observed a higher
attrition rate in men who were more distressed and
had more comorbidities at baseline. It is unknown
whether attrition in this subset of men was due to
a lack of more intensive support services, such as
extensive one-on-one counseling. Findings suggest
that this interactive, comprehensive education and
decision aid program is most effective for a subset
of patients who might be at risk for unmet support
needs and decisional distress related to prostate cancer treatment decision-making.
Given the results, it is critical to be able to identify
at-risk patients in need of decision support services
as well as when and how to deliver these services.
The benefit of the Healing Choices program was
reflected in patients’ perceptions of having received
better advice, guidance, and decision-making support compared to the standard consultation alone.
This was particularly true for African-American
men and limited evidence suggested that this effect
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also applied to men with lower education. Minority
patients and those from lower socioeconomic background receive less information and emotional support from providers than nonminority patients from
higher socioeconomic background [39]. Providers
may also change their counseling practices and clinical management based on patients’ socioeconomic
status [40] in part due to misperceptions about
patients’ desire and need for information and ability
to take part in the care process [41].
Poor prostate cancer knowledge may also stem
from low health literacy, particularly in patients of
disadvantaged socioeconomic backgrounds, which
relates to lower self-efficacy in making prostate cancer treatment decisions and greater decisional conflict [27,28]. The Healing Choice program may have
filled these gaps in care or added additional support
to those who struggled to understand information
provided in the clinical setting.
These results provide context for the ways in
which decision aids may be used in real-world contexts in conjunction with other available resources
and support. It may be that certain subgroups of
patients would benefit from additional support provided by a decision aid, whereas others’ needs are
adequately met by publicly available services such
as the CIS. Early identification of patients that may
benefit from enhanced support services will help to
mitigate or avoid distress related to decision uncertainty for patients. Further investigation of ways to
assess and triage patients into “stepped up” decision
support and how this may be seamlessly integrated
into existing, population-based services is warranted.
Interventions also need to be refined to target
underserved populations and tailored to meet
the specific decision support needs of patient subgroups. Future work is needed to determine the
best ways to leverage technology to provide tailored
interventions and how to best integrate them at
multiple levels of care. The CIS program is a population-based resource in which callers may benefit from being referred to additional decision aid
resources when needed. Clinical resources, such
as patient portals, may also integrate decision aids
for patients. Integration of evidence-based decision
support resources into existing real-world services
and settings will increase the reach of these interventions, while also conserving clinical resources.
Of note, patients do have varying levels of preferred involvement in treatment decision-making.
Older age, being male, lower educational attainment, and poorer socioeconomic status correlate
with a preference for less active roles in the decision-making process [42–44]. Men who find it difficult to access or understand medical information
about risks may experience anxiety about taking
responsibility for treatment outcomes [45]. Some
men also may be reluctant to challenge providers
recommendations and do not want to be seen as a

difficult or disrespectful patient [45], which would
naturally limit their involvement and opportunity to
ask questions about their specific concerns. Indeed,
it is possible that African-American men and those
with lower education who benefitted most from the
Healing Choices program had, at baseline, the expectancy that understandable information would not be
readily available from the medical team; an assertion justified by the literature [39]. To the extent that
these biases were operating on the part of patients
or medical professionals, the intervention may have
improved the degree to which men felt they had
enough guidance, advice, and support to make treatment decisions, potentially leading to more active
decision-making roles. Passive decision-making has
been associated with later regret and retrospective
criticism of provider interactions [44–46]. Decision
aids for prostate cancer treatment have resulted
in a greater proportion of patients wanting and
assuming an active role in decision-making [47,48].
Research is needed to develop targeted decision
support interventions that address patients’ preferences for involvement, thereby promoting a model
of collaborative, shared decision-making between
patients and providers that fits patients’ desired decision-making role and treatment outcomes.
There are several limitations that should be
considered and that might be associated with conducting research in a service environment within a
pragmatic trial. Due to concerns about subject burden, the assessment of decisional conflict was limited. It is therefore unknown whether participants
were experiencing decisional conflict before, during, or after their CIS standard consultation with an
information specialist. Although eligibility criteria
excluded men who had already made a treatment
decision, men did not have to be experiencing decision uncertainty or distress to participate. It is also
unknown how baseline levels of decisional conflict compared across study groups. Analyses were
unable to determine whether the Healing Choices
program was more or less effective for subgroups
of men with varying levels of decisional conflict
at different points in the decision-making process,
which may have also explained varying rates of
attrition across socio-demographic characteristics.
There was also limited baseline assessment of other
relevant factors such as information processing and
comprehension skills, illness cognitions, preferred
role in decision-making, and/or alternative sources
of support. We did not collect process data to evaluate the extent to which men accessed Healing Choices
and specific program components that may have
been more or less beneficial due to strict limitations
from the CIS about how many questions could be
asked of callers and the associated time burden to
callers. However, process-level data would inform
our understanding of decision support needs and
be important for future intervention development.
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Clinical disease characteristics such as cancer stage,
Gleason score, prognosis, and level of health literacy
may also be related to decision-making and the type
or extent of decision support needs that patients
have. Power analysis was conducted for main effects
and follow-up tests of interactions were exploratory.
CONCLUSION

Men diagnosed with early stage prostate cancer
face multiple treatment options with distinctive
side effect profiles and significant implications for
post-treatment quality of life. Healing Choices for Men
with Prostate Cancer is an educational and decision
aid program designed to support patients’ treatment
decision-making. Within the framework of an effectiveness study, patients with access to the program
reported significantly higher levels of decision support, compared with those who received standard
consultation through the CIS alone, and this intervention effect was greatest for African-American
men and those with lower educational attainment.
Future work is needed to evaluate potential reasons
for null findings regarding other aspects of the decision-making process and cancer-related distress and
to develop targeted strategies for addressing decision support needs in at-risk patient subgroups.
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